EP0573617A4 - - Google Patents

Info

Publication number
EP0573617A4
EP0573617A4 EP19920915059 EP92915059A EP0573617A4 EP 0573617 A4 EP0573617 A4 EP 0573617A4 EP 19920915059 EP19920915059 EP 19920915059 EP 92915059 A EP92915059 A EP 92915059A EP 0573617 A4 EP0573617 A4 EP 0573617A4
Authority
EP
European Patent Office
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
EP19920915059
Other versions
EP0573617A1 (en
Inventor
James A. Bianco
Stuart L. Bursten
Jack W. Singer
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Fred Hutchinson Cancer Center
Original Assignee
Fred Hutchinson Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fred Hutchinson Cancer Center filed Critical Fred Hutchinson Cancer Center
Priority to EP01126058A priority Critical patent/EP1214938A3/en
Publication of EP0573617A1 publication Critical patent/EP0573617A1/en
Publication of EP0573617A4 publication Critical patent/EP0573617A4/xx
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Steroid Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP92915059A 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli Ceased EP0573617A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP01126058A EP1214938A3 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US732227 1985-05-08
US70499291A 1991-05-24 1991-05-24
US704992 1991-05-24
US73222791A 1991-07-16 1991-07-16

Related Child Applications (1)

Application Number Title Priority Date Filing Date
EP01126058A Division EP1214938A3 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Publications (2)

Publication Number Publication Date
EP0573617A1 EP0573617A1 (en) 1993-12-15
EP0573617A4 true EP0573617A4 (enExample) 1994-02-09

Family

ID=27107424

Family Applications (2)

Application Number Title Priority Date Filing Date
EP92915059A Ceased EP0573617A1 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli
EP01126058A Withdrawn EP1214938A3 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Family Applications After (1)

Application Number Title Priority Date Filing Date
EP01126058A Withdrawn EP1214938A3 (en) 1991-05-24 1992-05-22 Modulation of cellular response to external stimuli

Country Status (7)

Country Link
EP (2) EP0573617A1 (enExample)
JP (1) JP3566719B2 (enExample)
AU (1) AU664189B2 (enExample)
CA (1) CA2109796C (enExample)
IE (1) IE921683A1 (enExample)
IL (1) IL101982A (enExample)
WO (1) WO1992021344A2 (enExample)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648357A (en) * 1992-03-04 1997-07-15 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds
CA2112239C (en) * 1992-03-04 2000-05-09 James A. Bianco Enantiomeric hydroxylated xanthine compounds
US5580873A (en) * 1992-03-04 1996-12-03 Cell Therapeutics, Inc. Enatiomerically pure hydroxylated xanthine compounds to treat proliferative vascular diseases
EP0728003A1 (en) 1993-11-12 1996-08-28 Cell Therapeutics, Inc. Method for preventing tissue injury from hypoxia
CA2192470A1 (en) * 1994-01-14 1995-07-20 Paul A. Brown Method for treating diseases mediated by cellular proliferation in response to pdgf, egf, fgf and vegf
AU1990195A (en) * 1994-03-08 1995-09-25 Cell Therapeutics, Inc. Use of compounds which inhibit phosphatidic acid formation for the manufacture of a medicament for the treatment of cancer
US5843943A (en) * 1994-12-29 1998-12-01 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US6323201B1 (en) 1994-12-29 2001-11-27 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
CA2208580A1 (en) * 1994-12-29 1996-07-11 The Regents Of The University Of California Compounds for inhibition of ceramide-mediated signal transduction
US5856330A (en) * 1996-07-31 1999-01-05 Hoechst Aktiengesellschaft Use of xanthine derivatives for the inhibition of dephosphorylation of cofilin
CA2335595A1 (en) * 1998-06-29 2000-01-06 The Regents Of The University Of California Bifunctional antagonists of cytokine-sensitive protein kinase activation cascades and methods for use as anti-inflammatory agents
US6930101B1 (en) 1999-05-17 2005-08-16 The Regents Of The University Of California Thiazolopyrimidines useful as TNFα inhibitors
US20110059994A1 (en) * 2008-01-31 2011-03-10 Korea Institute Of Science And Technology Composition for preventing or treating brain cancers
JP2011510976A (ja) * 2008-01-31 2011-04-07 韓国科学技術研究院 イノシトール１，４，５−三リン酸受容体サブタイプ３の阻害用の組成物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4636507A (en) * 1984-04-30 1987-01-13 Hoechst-Roussel Pharmaceuticals Inc. Host defense mechanism enhancement
GB8621869D0 (en) * 1986-09-11 1986-10-15 Beecham Group Plc Treatment
US4965271A (en) * 1986-12-31 1990-10-23 Hoechst Roussel Pharmaceuticals, Inc. Method of inhibiting the activity of leukocyte derived cytokines
IL106861A (en) * 1986-12-31 1997-02-18 Hoechst Roussel Pharma Pentoxifylline metabolites and pharmaceutical formulations containing them for inhibiting the activity of interleukin-1 and leukocyte-derived cytokines
JPH0344324A (ja) * 1989-07-13 1991-02-26 Kazuoki Tsuchiya 性機能賦活剤
US5112827A (en) * 1990-05-18 1992-05-12 Board Of Regents, The University Of Texas System Drug to reverse fatty liver and atheromatous lesions
EP0493682A3 (en) * 1990-11-30 1992-11-19 Hoechst-Roussel Pharmaceuticals Incorporated Use of xanthines for the preparation of a medicament effective for inhibiting the effects of allograft reaction in humans
IL100195A0 (en) * 1990-11-30 1992-08-18 Hoechst Roussel Pharma Use of xanthines for the preparation of a medicament having immuno suppressing activity
ES2093138T3 (es) * 1991-05-23 1996-12-16 Hoechst Ag El empleo de 1-(5-oxohexil)-3-metil-7-n-propil-xantina en cirugia vascular.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
G.A. DOSREIS ET AL: "Purinergic modulation of T-lymphocyte activation: differential susceptibility of distinct activation steps and correlation with intracellular 3',5'-cyclic adenosine monophosphate accumulation.", CELL IMMUNOL., vol. 101, no. 1, 1986, pages 213 - 231 *

Also Published As

Publication number Publication date
JP3566719B2 (ja) 2004-09-15
IL101982A0 (en) 1992-12-30
WO1992021344A3 (en) 1993-12-09
AU664189B2 (en) 1995-11-09
IE921683A1 (en) 1992-12-02
WO1992021344A2 (en) 1992-12-10
CA2109796A1 (en) 1992-12-10
EP1214938A2 (en) 2002-06-19
IL101982A (en) 2000-02-29
CA2109796C (en) 2004-04-27
EP1214938A3 (en) 2003-08-06
EP0573617A1 (en) 1993-12-15
JPH07500085A (ja) 1995-01-05
AU2247592A (en) 1993-01-08

Similar Documents

Publication Publication Date Title
DK0526024T3 (enExample)
EP0497252A3 (enExample)
IN187002B (enExample)
EP0536964A3 (enExample)
DE4290898T1 (enExample)
DE4291684T1 (enExample)
DE4291066T1 (enExample)
DE4291110T1 (enExample)
JPH0497731U (enExample)
JPH0493588U (enExample)
JPH0494606U (enExample)
ECSM91577U (enExample)
JPH0494742U (enExample)
ECSM91572U (enExample)
EP0573617A4 (enExample)
EP0500048A3 (enExample)
EP0518695A3 (enExample)
EP0495203A3 (enExample)
CN3009376S (enExample)
EP0521236A3 (enExample)
CN3009079S (enExample)
AU8894791A (enExample)
AU8794191A (enExample)
CN3009740S (enExample)
EP0524612A3 (enExample)

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19930923

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19931217

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19961008

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN REFUSED

18R Application refused

Effective date: 20020306